Advancing Through Clinical Innovation
Tactical Therapeutics is actively advancing clinical development of its lead therapy, CTO (Carboxyamidotriazole Orotate), through studies focused on safety, efficacy, and real-world impact in patients with limited treatment options.
Our clinical program is designed to validate a new approach to targeting cancer resistance.
Current Focus
Focused on High-Unmet-Need Patients
Our clinical trials primarily focus on patients with advanced and recurrent cancers, including glioblastoma, where standard therapies have failed or provide limited benefit.
By targeting these populations, we aim to deliver meaningful outcomes where the need is greatest.
Clinical Development of CTO
- Safety and tolerability
- Tumor response and disease control
- Drug distribution and brain penetration
- Impact on progression and survival
Encouraging Early Outcomes
Clinical data to date demonstrate promising activity in patients with advanced solid tumors, newly diagnosed and recurrent glioblastoma (ngbm & rgbm).
Why It Matters
A New Direction in Clinical Oncology
Traditional Therapies Often Fail
Traditional therapies often fail due to resistance and limited ability to reach tumor sites—especially in the brain. CTO is designed to address both challenges.
By combining multi-pathway targeting with effective delivery, our clinical program represents a potential shift in how aggressive cancers are treated.
Expanding Clinical Opportunities
Tactical Therapeutics is preparing for the next stages of clinical development, including expanded trials and broader applications across additional solid tumors.
We are actively exploring opportunities to accelerate development through strategic partnerships and collaborations.